Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 00847X104 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Farallon Capital Management, L.L.C.
13G/A
Amendment 5
|
9.9% |
8/3/2026
Event 6/30/2026
|
|
| Farallon Capital Management, L.L.C. | 9.9% | ||
| Farallon Capital Partners, L.P. | 0% | ||
| Farallon Capital Institutional Partners, L.P. | 0% | ||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||
| Four Crossings Institutional Partners V, L.P. | 0% | ||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||
| Farallon Capital (AM) Investors, L.P. | 0% | ||
| Farallon Capital F5 Master I, L.P. | 0% | ||
| Farallon Healthcare Partners Master, L.P. | 0% | ||
| Farallon Partners, L.L.C. | 0% | ||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||
| Farallon F5 (GP), L.L.C. | 0% | ||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | ||
| Dapice Joshua J. | 9.9% | ||
| Dreyfuss, Philip D. | 9.9% | ||
| Dunn Hannah E. | 9.9% | ||
| Gehani, Varun N. | 9.9% | ||
| Giauque, Nicolas | 9.9% | ||
| Husen, Avner A. | 9.9% | ||
| Kim, David T. | 9.9% | ||
| Linn, Michael G. | 9.9% | ||
| Luo Patrick (Cheng) | 9.9% | ||
| Roberts, Jr., Thomas G. | 9.9% | ||
| Saito Edric C. | 9.9% | ||
| Short Daniel S. | 9.9% | ||
| Spokes, Andrew J. M. | 9.9% | ||
| Warren, John R. | 9.9% | ||
| Wehrly, Mark C. | 9.9% | ||
|
D. E. Shaw & Co., L.P.
13G
|
5.1% |
7/2/2026
Event 6/25/2026
|
|
| D. E. Shaw & Co., L.P. | 5.1% | ||
| David E. Shaw | 5.1% | ||
|
Armistice Capital, LLC
13G/A
Amendment 1
|
4.6% |
5/15/2026
Event 3/31/2026
|
|
| Armistice Capital, LLC | 4.6% | ||
| Steven Boyd | 4.6% | ||
|
Lynx1 Capital Management LP
13G
|
5.1% |
5/6/2026
Event 4/29/2026
|
|
| Lynx1 Capital Management LP | 5.1% | ||
| Weston Nichols | 5.1% | ||
| Vanguard Capital Management LLC 13G | 5.3% |
4/29/2026
Event 3/31/2026
|
|
| Vanguard Group Inc 13G/A Amendment 10 | 0% |
3/26/2026
Event 3/13/2026
|
|
|
Armistice Capital, LLC
13G
|
5.2% |
2/17/2026
Event 12/31/2025
|
|
| Armistice Capital, LLC | 5.2% | ||
| Steven Boyd | 5.2% | ||
|
Farallon Capital Partners, L.P.
13G/A
Amendment 4
|
8.8% |
2/9/2026
Event 12/31/2025
|
|
| Farallon Capital Partners, L.P. | 0.7% | ||
| Farallon Capital Institutional Partners, L.P. | 0.8% | ||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||
| Farallon Capital Offshore Investors II, L.P. | 1.6% | ||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||
| Farallon Healthcare Partners Master, L.P. | 5.0% | ||
| Farallon Partners, L.L.C. | 8.7% | ||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||
| Farallon F5 (GP), L.L.C. | 0.2% | ||
| Farallon Healthcare Partners (GP), L.L.C. | 5.0% | ||
| Dapice Joshua J. | 8.8% | ||
| Dreyfuss, Philip D. | 8.8% | ||
| Dunn Hannah E. | 8.8% | ||
| Fried, Richard B | 0% | ||
| Gehani, Varun N. | 8.8% | ||
| Giauque, Nicolas | 8.8% | ||
| Husen, Avner A. | 8.8% | ||
| Kim, David T. | 8.8% | ||
| Linn, Michael G. | 8.8% | ||
| Luo Patrick (Cheng) | 8.8% | ||
| Patel, Rajiv A. | 0% | ||
| Roberts, Jr., Thomas G. | 8.8% | ||
| Saito Edric C. | 8.8% | ||
| Seybold, William | 0% | ||
| Short Daniel S. | 8.8% | ||
| Spokes, Andrew J. M. | 8.8% | ||
| Warren, John R. | 8.8% | ||
| Wehrly, Mark C. | 8.8% | ||
| State Street Corp 13G | 5.3% |
2/9/2026
Event 12/31/2025
|
|
|
Bellevue Group AG
13G/A
Amendment 1
|
0% |
12/5/2025
Event 11/19/2025
|
|
| Bellevue Group AG | 0% | ||
| Bellevue Asset Management AG | 0% | ||
|
Paradigm Biocapital Advisors LP
13G/A
Amendment 1
|
4.9% |
11/14/2025
Event 9/30/2025
|
|
| Paradigm BioCapital Advisors LP | 4.9% | ||
| Paradigm BioCapital Advisors GP LLC | 4.9% | ||
| Senai Asefaw, M.D. | 4.9% | ||
| Paradigm BioCapital International Fund Ltd. | 4.4% | ||
|
Paradigm Biocapital Advisors LP
13G
|
5.2% |
8/28/2025
Event 8/21/2025
|
|
| Paradigm BioCapital Advisors LP | 5.2% | ||
| Paradigm BioCapital Advisors GP LLC | 5.2% | ||
| Senai Asefaw, M.D. | 5.2% | ||
| Paradigm BioCapital International Fund Ltd. | 4.6% | ||
| BlackRock, Inc. 13G/A Amendment 7 | 7.8% |
7/17/2025
Event 6/30/2025
|
|
|
Bellevue Group AG
13G
|
6.1% |
7/7/2025
Event 6/1/2025
|
|
| Bellevue Group AG | 6.1% | ||
| Bellevue Asset Management AG | 6.1% | ||
|
BB Biotech AG
13G/A
Amendment 12
|
0% |
6/13/2025
Event 6/1/2025
|
|
| BB Biotech AG | 0% | ||
| Biotech Target N.V. | 0% | ||
|
BB Biotech AG
13G/A
Amendment 11
|
6.2% |
2/14/2025
Event 12/31/2024
|
|
| BB Biotech AG | 6.2% | ||
| Biotech Target N.V. | 6.2% | ||
|
Farallon Capital Partners, L.P.
13G/A
Amendment 3
|
9.9% |
2/4/2025
Event 12/31/2024
|
|
| Farallon Capital Partners, L.P. | 0.7% | ||
| Farallon Capital Institutional Partners, L.P. | 0.8% | ||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||
| Farallon Capital Offshore Investors II, L.P. | 1.5% | ||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||
| Farallon Capital F5 Master I, L.P. | 0.4% | ||
| Farallon Healthcare Partners Master, L.P. | 5.8% | ||
| Farallon Partners, L.L.C. | 9.6% | ||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||
| Farallon F5 (GP), L.L.C. | 0.4% | ||
| Farallon Healthcare Partners (GP), L.L.C. | 5.8% | ||
| Dapice Joshua J. | 9.9% | ||
| Dreyfuss, Philip D. | 9.9% | ||
| Dunn Hannah E. | 9.9% | ||
| Fried, Richard B | 9.9% | ||
| Gehani, Varun N. | 9.9% | ||
| Giauque, Nicolas | 9.9% | ||
| Kim, David T. | 9.9% | ||
| Linn, Michael G. | 9.9% | ||
| Luo Patrick (Cheng) | 9.9% | ||
| Patel, Rajiv A. | 9.9% | ||
| Roberts, Jr., Thomas G. | 9.9% | ||
| Saito Edric C. | 9.9% | ||
| Seybold, William | 9.9% | ||
| Short Daniel S. | 9.9% | ||
| Spokes, Andrew J. M. | 9.9% | ||
| Warren, John R. | 9.9% | ||
| Wehrly, Mark C. | 9.9% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 3.35 k | $111 k |
| 2026 Q2 | 254 | 68.6 M | $2.52 B |
| 2026 Q1 | 251 | 63.1 M | $2.12 B |
| 2025 Q4 | 261 | 61.3 M | $1.67 B |
| 2025 Q3 | 249 | 63.7 M | $2.55 B |
| 2025 Q2 | 228 | 62.3 M | $2.07 B |
| 2025 Q1 | 235 | 60.1 M | $1.76 B |
| 2024 Q4 | 240 | 59.8 M | $1.97 B |
| 2024 Q3 | 231 | 59.9 M | $2.66 B |
| 2024 Q2 | 226 | 60.8 M | $2.62 B |
| 2024 Q1 | 211 | 67.1 M | $1.96 B |
| 2023 Q4 | 189 | 63.8 M | $1.42 B |
| 2023 Q3 | 164 | 59.4 M | $1.47 B |
| 2023 Q2 | 168 | 59.4 M | $1.68 B |
| 2023 Q1 | 180 | 59.2 M | $1.36 B |
| 2022 Q4 | 179 | 62.7 M | $1.76 B |
| 2022 Q3 | 190 | 58.4 M | $1.65 B |
| 2022 Q2 | 172 | 59.2 M | $1.31 B |
| 2022 Q1 | 184 | 60.2 M | $1.75 B |
| 2021 Q4 | 183 | 59.4 M | $1.95 B |
| 2021 Q3 | 180 | 60.9 M | $2.81 B |
| 2021 Q2 | 205 | 65.9 M | $3.63 B |
| 2021 Q1 | 195 | 65.3 M | $3.37 B |
| 2020 Q4 | 234 | 65.6 M | $2.84 B |
| 2020 Q3 | 231 | 65.9 M | $2.30 B |
| 2020 Q2 | 240 | 67.9 M | $3.63 B |
| 2020 Q1 | 227 | 69.6 M | $2.48 B |
| 2019 Q4 | 226 | 70.0 M | $3.34 B |
| 2019 Q3 | 212 | 63.1 M | $2.05 B |
| 2019 Q2 | 214 | 61.3 M | $3.06 B |
| 2019 Q1 | 224 | 60.1 M | $4.06 B |
| 2018 Q4 | 218 | 58.6 M | $2.70 B |
| 2018 Q3 | 231 | 57.0 M | $4.39 B |
| 2018 Q2 | 238 | 54.9 M | $4.63 B |
| 2018 Q1 | 216 | 55.7 M | $4.55 B |
| 2017 Q4 | 193 | 47.0 M | $2.69 B |
| 2017 Q3 | 186 | 46.1 M | $3.07 B |
| 2017 Q2 | 183 | 46.2 M | $2.37 B |
| 2017 Q1 | 170 | 41.1 M | $2.40 B |
| 2016 Q4 | 177 | 39.1 M | $1.63 B |
| 2016 Q3 | 177 | 37.9 M | $2.00 B |
| 2016 Q2 | 167 | 34.1 M | $1.43 B |
| 2016 Q1 | 169 | 33.8 M | $1.37 B |
| 2015 Q4 | 161 | 33.2 M | $2.15 B |
| 2015 Q3 | 161 | 31.5 M | $2.22 B |
| 2015 Q2 | 170 | 30.1 M | $3.35 B |
| 2015 Q1 | 159 | 28.0 M | $2.64 B |
| 2014 Q4 | 155 | 27.7 M | $3.10 B |
| 2014 Q3 | 125 | 24.5 M | $1.50 B |
| 2014 Q2 | 105 | 24.9 M | $1.14 B |
| 2014 Q1 | 76 | 20.5 M | $804 M |